"id","versionIdentifier","rationale","uuid:ID","instanceType"
"StudyVersion_1","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","5a0dc812-8fd5-4028-9395-2fb8464ecd89","StudyVersion"
